Access to Minimally Invasive Surgery for Advanced Ovarian Cancer Varies Widely by Facility
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
No Definitive Link Found Between Female Infertility and Gynecological Cancer
Ronald D. Alvarez, MD, MBA, analyzes recent changes to NCCN guidelines for ovarian cancer care and provides updates on the latest clinical trial data.
The Use of PARP Inhibitors in Ovarian Cancer
Earlier Introduction of Antibody-Drug Conjugates
The Role of Novel Targeted Therapies
Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
Improving Clinician Awareness and Adoption of Molecular Testing
The Impact of Tumor Heterogeneity in Ovarian Cancer
Comprehensive Molecular Testing in Patients With Ovarian Cancer
Emerging Molecular Biomarkers in Ovarian Cancer
FRα Biomarker Testing in Patients With Ovarian Cancer
The Role of Guidelines on Molecular Testing in Ovarian Cancer
Ovarian Cancer Outcomes Linked to Preoperative Immunonutritional Status
Revealing Ovarian Cancer Survival Gaps Among Asian American Subgroups